15 March 2023
PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies, announced the acceptance of a poster presentation about RS-0139 at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as “The Home of Phase I in Oncology”.
PDC Therapeutics’ platform technology allows designing targeted drug candidates for therapies with no compromise in different therapeutic areas. The nanocarriers introduce a versatile targeting capability and are suitable for loading a single or a combination of chemotherapeutic agents with superior pharmacokinetic profiles, while the targeting enables the drugs to accumulate in the tumor, ensuring an enhanced therapeutic index and thus offering reduced toxicity profile.
RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the superior therapeutic index that SagittaTM platforms are ready to offer. The ongoing Phase I clinical trial aims to deliver docetaxel specifically into integrin-expressing tumors. RS Research Medical Director Dr. Gülşah Nomak is going to present the candidates’ promising preclinical data at ESMO TAT 2023.
Poster Title: RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Date: 6 March 2023
Poster No: 100P
Presenter: Prof. Rana Sanyal, PhD; Gülşah Nomak, MD
The poster abstract is available online at the ESMO TAT 2023 website.
PDC Therapeutics is a biotech company developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. PDC Therapeutics’ proprietary clinically validated drug delivery technology SagittaTM can help discover and develop smart nanomedicines for therapies with no compromise.
For detailed information: